Troy– Author –
-
Leading AI Drug Discovery Platforms Evolve from Candidate Generation to Protein Design in 2026, Driven by Eli Lilly-Insilico Medicine $2.75 Billion Partnership
The AI Journal USA Overview In 2026, AI drug discovery platforms, led by Converge Bio, Xaira Therapeutics, and Generate Biomedicines, have advanced beyond mere drug prediction to encompass candidate generation, antibody engineering, targ... -
Domo Unveils AI Agent Platform for Data-Driven Teams, Competing with Salesforce Agentforce and Google Vertex AI Agent Builder
Domo USA Overview Domo has launched an AI agent platform for data-driven teams, enabling the creation of autonomous programs capable of reasoning, acting, and completing tasks. This platform can execute API calls and database queries, ad... -
STMicroelectronics Advances Edge AI with STM32, Enabling Real-time Processing via ST Edge AI Suite for Model Optimization and C Code Compilation
STMicroelectronics Community Switzerland Overview STMicroelectronics is enabling Edge AI directly on STM32 microcontrollers and microprocessors, delivering superior power efficiency, ultra-low latency, real-time applications, and enhance... -
Crunchbase Data Reveals US AI Startup Funding to Dominate Globally with $319 Billion by 2026, Widening Gap with Non-US Counterparts
Crunchbase USA Overview According to the latest Crunchbase data, AI startup funding is overwhelmingly concentrated in the US, projected to reach $319 billion by 2026. This starkly contrasts with the $45 billion raised by non-US startups,... -
Multimodal AI Expands Human-like Perception, Led by Gemini 2.5 Pro and GPT-5 Integrating Text, Image, and Audio for Next-Gen Systems
Simplilearn International Overview Multimodal AI is achieving more human-like perception by simultaneously processing inputs from diverse sources like text, images, audio, video, and sensor data, and generating multi-format outputs. Mode... -
FDA Approves First AI-Designed Drug Molecule for Phase 3 Clinical Trial in 2026, Accelerating R&D with New AI Drug Discovery Regulatory Guidance
BioNixus USA Overview In March 2026, the US FDA approved the first AI-designed drug molecule for Phase 3 clinical trials, solidifying AI drug discovery as a foundational technology in pharmaceutical R&D. Following this, on May 15th, ... -
Sky9 Capital Reports 2026 AI Startup Funding Tightens Amid Soaring Computing Costs and Difficulty in Model Differentiation
Sky9 Capital International Overview AI startup funding in 2026 has become more selective due to escalating computing costs and challenges in model differentiation. According to Sky9 Capital's analysis, successful founders are now require... -
OpenAI and Broadcom Unveil LLM-Optimized AI Chip “Jalapeño,” Significantly Outperforming State-of-the-Art in Performance per Watt
OpenAI / Broadcom USA Overview OpenAI and Broadcom have announced "Jalapeño," a custom AI chip specifically designed for Large Language Model (LLM) inference. This chip significantly surpasses current state-of-the-art products in perform... -
Google Invests $75 Million in A24, Partnering with DeepMind to Revolutionize Film Production and Distribution Tools via AI
Quartz USA Overview Google has invested $75 million in independent film studio A24 and established an AI research partnership with DeepMind aimed at developing innovative new tools for film production and distribution. This landmark inve... -
Leading AI Coding Agents in 2026 Comprehend Multi-File Context, Revolutionizing Development Efficiency with Autonomous Code Generation, Modification, and Debugging
Kiro USA Overview In 2026, prominent AI coding agents like Windsurf, Cline, Factory AI, Kiro, Codex CLI, Manus, and Aider are demonstrating capabilities far beyond mere code completion. They understand multi-file contexts, plan and execu...
